Matches in SemOpenAlex for { <https://semopenalex.org/work/W4353020724> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4353020724 endingPage "107815522311635" @default.
- W4353020724 startingPage "107815522311635" @default.
- W4353020724 abstract "Introduction Peripherally acting μ-opioid receptor antagonists (PAMORAs) are used in the treatment of opioid induced constipation without impacting the actions of opioid analgesics. Subcutaneous methylnaltrexone was one of the first PAMORAs approved in April 2008 for the treatment of opioid induced constipation in adult patients. The safety and effectiveness of methylnaltrexone has not been established in pediatric patients. In this study, the use of subcutaneous methylnaltrexone in pediatric patients is analyzed and reviewed. The primary outcome is occurrence of a bowel movement within 24 h after methylnaltrexone (MNTX) administration and the number of bowel movements following treatment with methylnaltrexone. Secondary outcomes include safety in this patient cohort. Methods This is a retrospective study of 79 pediatric patients with opioid induced constipation. Patients were administered methylnaltrexone during their inpatient stay. Data on bowel activity after methylnaltrexone was obtained from the hospital information system. Results Out of the 79 patients who received methylnaltrexone, there were seven patients from whom data could not be analyzed. Of the 72 patients whose data was available, 38% ( N = 27) were documented as having a bowel movement, 62% ( N = 45) did not have a bowel movement. Reported adverse events were minimal with nausea ( N = 3), vomiting ( N = 1), and flatulence ( N = 6). Conclusion Methylnaltrexone appears safe in the pediatric population and produces bowel movements in more than a third of pediatric patients. It is a feasible and safe option for opioid induced constipation in pediatric patients." @default.
- W4353020724 created "2023-03-23" @default.
- W4353020724 creator A5022590351 @default.
- W4353020724 creator A5026131694 @default.
- W4353020724 creator A5040371150 @default.
- W4353020724 creator A5078914553 @default.
- W4353020724 creator A5079394261 @default.
- W4353020724 date "2023-03-22" @default.
- W4353020724 modified "2023-09-24" @default.
- W4353020724 title "The safety and efficacy of methylnaltrexone in pediatric oncology patients: A single center experience" @default.
- W4353020724 cites W1594674059 @default.
- W4353020724 cites W1946103103 @default.
- W4353020724 cites W1965033987 @default.
- W4353020724 cites W1972105972 @default.
- W4353020724 cites W1996075855 @default.
- W4353020724 cites W2013247619 @default.
- W4353020724 cites W2021478061 @default.
- W4353020724 cites W2065804379 @default.
- W4353020724 cites W2158281754 @default.
- W4353020724 cites W2164341191 @default.
- W4353020724 cites W2172882315 @default.
- W4353020724 cites W2402823822 @default.
- W4353020724 cites W2801609795 @default.
- W4353020724 cites W3001207921 @default.
- W4353020724 doi "https://doi.org/10.1177/10781552231163540" @default.
- W4353020724 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36946143" @default.
- W4353020724 hasPublicationYear "2023" @default.
- W4353020724 type Work @default.
- W4353020724 citedByCount "0" @default.
- W4353020724 crossrefType "journal-article" @default.
- W4353020724 hasAuthorship W4353020724A5022590351 @default.
- W4353020724 hasAuthorship W4353020724A5026131694 @default.
- W4353020724 hasAuthorship W4353020724A5040371150 @default.
- W4353020724 hasAuthorship W4353020724A5078914553 @default.
- W4353020724 hasAuthorship W4353020724A5079394261 @default.
- W4353020724 hasConcept C108797546 @default.
- W4353020724 hasConcept C126322002 @default.
- W4353020724 hasConcept C170493617 @default.
- W4353020724 hasConcept C197934379 @default.
- W4353020724 hasConcept C2780580376 @default.
- W4353020724 hasConcept C2780852908 @default.
- W4353020724 hasConcept C2781063702 @default.
- W4353020724 hasConcept C2781112942 @default.
- W4353020724 hasConcept C42219234 @default.
- W4353020724 hasConcept C71924100 @default.
- W4353020724 hasConceptScore W4353020724C108797546 @default.
- W4353020724 hasConceptScore W4353020724C126322002 @default.
- W4353020724 hasConceptScore W4353020724C170493617 @default.
- W4353020724 hasConceptScore W4353020724C197934379 @default.
- W4353020724 hasConceptScore W4353020724C2780580376 @default.
- W4353020724 hasConceptScore W4353020724C2780852908 @default.
- W4353020724 hasConceptScore W4353020724C2781063702 @default.
- W4353020724 hasConceptScore W4353020724C2781112942 @default.
- W4353020724 hasConceptScore W4353020724C42219234 @default.
- W4353020724 hasConceptScore W4353020724C71924100 @default.
- W4353020724 hasLocation W43530207241 @default.
- W4353020724 hasLocation W43530207242 @default.
- W4353020724 hasOpenAccess W4353020724 @default.
- W4353020724 hasPrimaryLocation W43530207241 @default.
- W4353020724 hasRelatedWork W2097211888 @default.
- W4353020724 hasRelatedWork W2358657645 @default.
- W4353020724 hasRelatedWork W2362740208 @default.
- W4353020724 hasRelatedWork W2372689149 @default.
- W4353020724 hasRelatedWork W2373112319 @default.
- W4353020724 hasRelatedWork W2403521446 @default.
- W4353020724 hasRelatedWork W2528959283 @default.
- W4353020724 hasRelatedWork W2758389726 @default.
- W4353020724 hasRelatedWork W4253296575 @default.
- W4353020724 hasRelatedWork W4292647012 @default.
- W4353020724 isParatext "false" @default.
- W4353020724 isRetracted "false" @default.
- W4353020724 workType "article" @default.